Merck, Daiichi scrap FDA application for B7-H3 ADC in lung cancer

NDA FilingrejectedNegative

AI Analysis

Summary

Merck and Daiichi Sankyo have withdrawn their FDA accelerated approval application for an antibody-drug conjugate in small cell lung cancer, marking another setback in their partnership.

Outcome Details

FDA accelerated approval application withdrawn

Importance:7/10

Sentiment:

-0.90

FDAADClung canceraccelerated approvalapplication withdrawalpartnership setback

Related Companies

$MRK $DSKYF

Read the original article

Published by Endpoints News on September 28, 2026 11:13 AM

Read Original